Search

Dwayne C. Jones

Examiner (ID: 17153, Phone: (571)272-0578 , Office: P/3991 )

Most Active Art Unit
1614
Art Unit(s)
1205, 1614, 1204, 3991
Total Applications
1333
Issued Applications
842
Pending Applications
270
Abandoned Applications
221

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19067123 [patent_doc_number] => 20240101549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES [patent_app_type] => utility [patent_app_number] => 18/257123 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 123052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -311 [patent_words_short_claim] => 455 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257123 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/257123
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES Dec 15, 2021 Pending
Array ( [id] => 19003542 [patent_doc_number] => 20240067613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/269169 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269169 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/269169
NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF Dec 13, 2021 Pending
Array ( [id] => 20492612 [patent_doc_number] => 12534474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Dihydrofuropyridine derivatives as rho-kinase inhibitors [patent_app_type] => utility [patent_app_number] => 18/267222 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19354 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267222 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/267222
Dihydrofuropyridine derivatives as rho-kinase inhibitors Dec 12, 2021 Issued
Array ( [id] => 17791958 [patent_doc_number] => 20220251049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 17/547660 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547660 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/547660
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Dec 9, 2021 Abandoned
Array ( [id] => 18955058 [patent_doc_number] => 20240043385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE [patent_app_type] => utility [patent_app_number] => 18/256094 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256094 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/256094
ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE Dec 9, 2021 Pending
Array ( [id] => 18844439 [patent_doc_number] => 20230406843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => Progranulin Modulators and Methods of Using the Same [patent_app_type] => utility [patent_app_number] => 18/038749 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038749 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/038749
Progranulin Modulators and Methods of Using the Same Dec 9, 2021 Abandoned
Array ( [id] => 18955119 [patent_doc_number] => 20240043446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE [patent_app_type] => utility [patent_app_number] => 18/256130 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256130 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/256130
ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE Dec 9, 2021 Pending
Array ( [id] => 17704497 [patent_doc_number] => 20220204503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/643083 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17643083 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/643083
Bicyclic heterocycle compounds and their uses in therapy Dec 6, 2021 Issued
Array ( [id] => 20402215 [patent_doc_number] => 12492183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Tetrahydroquinazoline derivatives as selective cytotoxic agents [patent_app_type] => utility [patent_app_number] => 18/254917 [patent_app_country] => US [patent_app_date] => 2021-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24403 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254917 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/254917
Tetrahydroquinazoline derivatives as selective cytotoxic agents Dec 5, 2021 Issued
Array ( [id] => 18971839 [patent_doc_number] => 20240051931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => HDAC INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/039941 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51565 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039941 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/039941
HDAC INHIBITORS Dec 1, 2021 Pending
Array ( [id] => 19067115 [patent_doc_number] => 20240101541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => COMPOUNDS FOR THE TREATMENT OF SARS [patent_app_type] => utility [patent_app_number] => 18/255341 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255341 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/255341
COMPOUNDS FOR THE TREATMENT OF SARS Nov 29, 2021 Pending
Array ( [id] => 19067142 [patent_doc_number] => 20240101568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => NOVEL BENZAZEPINE SPIRO DERIVATIVE [patent_app_type] => utility [patent_app_number] => 18/253935 [patent_app_country] => US [patent_app_date] => 2021-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253935 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/253935
NOVEL BENZAZEPINE SPIRO DERIVATIVE Nov 24, 2021 Pending
Array ( [id] => 20505874 [patent_doc_number] => 12540141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => Spiropyrrolidine derived antiviral agents [patent_app_type] => utility [patent_app_number] => 17/531874 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58985 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 308 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531874 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/531874
Spiropyrrolidine derived antiviral agents Nov 21, 2021 Issued
Array ( [id] => 17460243 [patent_doc_number] => 20220073548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/531159 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531159 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/531159
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use Nov 18, 2021 Issued
Array ( [id] => 19050787 [patent_doc_number] => 20240092756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => METHODS AND COMPOSITION FOR KRAS MODIFICATIONS [patent_app_type] => utility [patent_app_number] => 18/253712 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253712 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/253712
METHODS AND COMPOSITION FOR KRAS MODIFICATIONS Nov 17, 2021 Pending
Array ( [id] => 19528100 [patent_doc_number] => 20240352002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/035262 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035262 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/035262
BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME Nov 17, 2021 Pending
Array ( [id] => 18879089 [patent_doc_number] => 20240002458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => NOVEL VHL SMALL MOLECULE PROBES [patent_app_type] => utility [patent_app_number] => 18/035502 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035502 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/035502
NOVEL VHL SMALL MOLECULE PROBES Nov 7, 2021 Pending
Array ( [id] => 18384487 [patent_doc_number] => 11655256 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-05-23 [patent_title] => Processes for making a solid-state form of relugolix [patent_app_type] => utility [patent_app_number] => 17/520642 [patent_app_country] => US [patent_app_date] => 2021-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 4829 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17520642 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/520642
Processes for making a solid-state form of relugolix Nov 5, 2021 Issued
Array ( [id] => 19815011 [patent_doc_number] => 20250073218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND [patent_app_type] => utility [patent_app_number] => 18/035033 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18035033 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/035033
NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND Nov 3, 2021 Pending
Array ( [id] => 19034058 [patent_doc_number] => 20240083873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/028213 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028213 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/028213
Pyrimidine carboxamide compound and application thereof Nov 2, 2021 Issued
Menu